drugset
drugset / Trial / NCT01369095

Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression

NCT01369095 ↗

Phase 2 Completed 976 enrolled Bristol-Myers Squibb
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of the study is to evaluate the efficacy of study drug (BMS-820836) as compared with continued Duloxetine/Escitalopram in the treatment of patients with treatment resistant depression (TRD).

Timeline

Start
2011-07
Primary completion
2013-05
Completion
2013-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator Duloxetine Small molecule 30 mg Oral
Comparator Duloxetine Small molecule 60 mg Oral
Comparator Escitalopram Small molecule 10 mg Oral
Comparator Escitalopram Small molecule 20 mg Oral
Subject Liafensine Small molecule 0.25 mg Oral
Subject Liafensine Small molecule 0.5 mg Oral
Subject Liafensine Small molecule 1 mg Oral
Subject Liafensine Small molecule 2 mg Oral

Indications

depressive disorder